Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezetimibe/rosuvastatin - Sanofi

Next Previous
Search
Drug Profile

Ezetimibe/rosuvastatin - Sanofi

Alternative Names: EXT 1036A; Rosuvastatin/ezetimibe - Sanofi; SPC ezetimibe/rosuvastatin

Latest Information Update: 24 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 24 Jan 2023 Ezetimibe/rosuvastatin is still in phase III trials for Hypercholesterolemia (Treatment-experienced) in China (PO)
  • 24 Jan 2023 Ezetimibe/rosuvastatin is still in phase III trials for Hypercholesterolemia in Italy, Bulgaria, Slovakia and Czhech Republic (PO)
  • 15 Jun 2022 Sanofi completes the phase III ROZEL trial in Hypercholesterolaemia (Treatment-experienced) in China (PO) (NCT04669041)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top